Literature DB >> 9368780

Prospects for adoptive T cell therapy.

C Yee1, S R Riddell, P D Greenberg.   

Abstract

Since the establishment of methods to isolate genes encoding cytotoxic T lymphocyte defined tumor antigens, several antigens have been identified and characterized for suitability as target antigens for immunotherapy. The development of innovative strategies to generate T cells targeting these antigens and lessons learned from clinical trials of adoptive immunotherapy of viral diseases should facilitate the design of clinical trials for specific adoptive immunotherapy of cancer.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9368780     DOI： 10.1016/s0952-7915(97)80052-0

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN： 0952-7915            Impact factor:   7.486


  21 in total

1.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Authors:  C Yee; J A Thompson; D Byrd; S R Riddell; P Roche; E Celis; P D Greenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-11       Impact factor: 11.205

2.  Effector CD4 cells are tolerized upon exposure to parenchymal self-antigen.

Authors:  Amy D Higgins; Marianne A Mihalyo; Adam J Adler
Journal:  J Immunol       Date:  2002-10-01       Impact factor: 5.422

3.  Silencing of endogenous IL-10 in human dendritic cells leads to the generation of an improved CTL response against human melanoma associated antigenic epitope, MART-1 27-35.

Authors:  Arvind Chhabra; Nitya G Chakraborty; Bijay Mukherji
Journal:  Clin Immunol       Date:  2008-01-14       Impact factor: 3.969

4.  Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.

Authors:  Charles G Drake; Amy D H Doody; Marianne A Mihalyo; Ching-Tai Huang; Erin Kelleher; Sowmya Ravi; Edward L Hipkiss; Dallas B Flies; Eugene P Kennedy; Meixiao Long; Patrick W McGary; Lee Coryell; William G Nelson; Drew M Pardoll; Adam J Adler
Journal:  Cancer Cell       Date:  2005-03       Impact factor: 31.743

5.  Yiqi zhuyu decoction combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer.

Authors:  Bo Cao; Shao-tang Li; Zhi Li; Wen-ling Deng
Journal:  Chin J Integr Med       Date:  2011-08-09       Impact factor: 1.978

Review 6.  Evolution of the management of colorectal cancer using integrative medicine.

Authors:  Shao-Tang Li; Pan Chi
Journal:  Chin J Integr Med       Date:  2011-01-22       Impact factor: 1.978

Review 7.  Immunotherapy and immunoescape in colorectal cancer.

Authors:  Guillermo Mazzolini; Oihana Murillo; Catalina Atorrasagasti; Juan Dubrot; Iñigo Tirapu; Miguel Rizzo; Ainhoa Arina; Carlos Alfaro; Arantza Azpilicueta; Carmen Berasain; José L Perez-Gracia; Alvaro Gonzalez; Ignacio Melero
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

8.  Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality.

Authors:  Suresh Kalathil; Amit A Lugade; Austin Miller; Renuka Iyer; Yasmin Thanavala
Journal:  Cancer Res       Date:  2013-02-19       Impact factor: 12.701

9.  In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy.

Authors:  Marianne A Mihalyo; Amy D H Doody; Jeremy P McAleer; Elizabeth C Nowak; Meixiao Long; Yi Yang; Adam J Adler
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

Review 10.  Natural killer cell immunotherapy for cancer: a new hope.

Authors:  S Srivastava; A Lundqvist; R W Childs
Journal:  Cytotherapy       Date:  2008       Impact factor: 5.414
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.